ArticleActa pharmaceutica Sinica. B2022
Enhanced uptake and anti-maturation effect of celastrol-loaded mannosylated liposomes on dendritic cells for psoriasis treatment.
Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 82 citations in OpenAlex.
- Can Microneedle-Nanocarrier Platforms Deliver True Tolerogenic Immunotherapy for Psoriasis?Vaccines · 2026Review
- Liposomal Delivery Systems for Allergen-Specific Immunotherapy: From Molecular Design to Clinical Application.Membranes · 2026Review
- Berberine-Mangiferin Self-Assembled Carrier-Free Hydrogel Suppresses NETosis for Augmented Psoriasis Treatment.Advanced healthcare materials · 2026Article
- Overcoming the Druggability Hurdles of Celastrol: A Critical Review of Advanced Drug Delivery Strategies.Biomolecules · 2026Review
- Research advances on protein-based microneedles for treatment of skin diseases: A review.Materials today. Bio · 2026Review
- Interdisciplinarity traditional Chinese medicine microneedles in skin disease treatment: Recent advances and challenges.Bioactive materials · 2026Review
- Simultaneous targeting of multiple etiological using a nanosized strategy for psoriasis management.Materials today. Bio · 2025Article
- A triple-targeting "nano-brake" remodeling the impaired immune microenvironment in skin lesions for psoriasis treatment.Materials today. Bio · 2025Article
- Psoriasis: A Multidimensional Review of Onset, Progression, Treatment, and the Evolution of Disease Models.Molecular diagnosis & therapy · 2025Review
- A Spleen-Targeted Tolerogenic mRNA-LNPs Vaccine for the Treatment of Experimental Asthma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Microneedle-Based Approaches for Skin Disease Treatment.Nano-micro letters · 2025Review
- Topical adhesive spatio-temporal nanosystem co-delivering chlorin e6 and HMGB1 inhibitor glycyrrhizic acid forActa pharmaceutica Sinica. B · 2025Article
- Pathophysiology and Treatment of Psoriasis: From Clinical Practice to Basic Research.Pharmaceutics · 2025Review
- Role of innate immune cells in multiple sclerosis.Frontiers in immunology · 2025Review
- Liposomes and Their Therapeutic Applications in Enhancing Psoriasis and Breast Cancer Treatments.Nanomaterials (Basel, Switzerland) · 2024Review
- Recent Approaches for the Topical Treatment of Psoriasis Using Nanoparticles.Pharmaceutics · 2024Review
- Nanotechnology in inflammation: cutting-edge advances in diagnostics, therapeutics and theranostics.Theranostics · 2024Review
- Integrative analysis of RNA-sequencing and microarray for the identification of adverse effects of UVB exposure on human skin.Frontiers in public health · 2024Article
- Topical Delivery of microRNA-125b by Framework Nucleic Acids for Psoriasis Treatment.International journal of nanomedicine · 2024Article
- New Insights in Psoriasis Management using Herbal Drug Nanocarriers.Current pharmaceutical design · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is an autoimmune skin disease in which dendritic cells (DCs) trigger the progression of psoriasis by complex interactions with keratinocytes and other immune cells. In the present study, we aimed to load celastrol, an anti-inflammatory ingredient isolated from Chinese herbs, on mannosylated liposomes to enhance DC uptake as well as to induce DC tolerance in an imiquimod-induced psoriasis-like mouse model. Mannose was grafted onto liposomes to target mannose receptors on DCs. The results demonstrated that compared with unmodified liposomes, DCs preferred to take up more fluorescence-labeled mannosylated liposomes. After loading celastrol into mannose-modified liposomes, they effectively inhibited the expression of maturation markers, including CD80, CD86 and MHC-II, on DCs both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.